Injectable opiate maintenance in the UK: Is it good clinical practice?
This paper reviews the current practice of injectable opiate treatment (IOT) in the United Kingdom, i.e. the "British system" of prescribing injectable heroin and methadone, and considers some of the clinical and ethical issues it raises. There is very limited research evidence supporting either the safety or effectiveness of IOT as practised in Britain. In particular there is almost no evaluation of long-term outcomes of IOT, which is of potential concern given the possibility of some patients remaining indefinitely in IOT, the risk of vascular complications, and its higher cost compared with oral maintenance. It would be easy to assess this controversial intervention as in need of further research. However, striving towards best practice in IOT involves more than generating evidence. The likelihood of a patient receiving IOT in the United Kingdom appears to be influenced more by the personal inclinations of prescribers than by outcome data (if any), or identified community needs for access to IOT. The author asks is this good clinical practice and is it sustainable? The "British system" needs to modernise itself consistent with international paradigms of continuous quality improvement, and the NHS's own agenda of clinical governance.
Zador
D
D
Drugs North West, Mental Health Services of Salford NHS Trust, Prestwich, Manchester, UK.
D000701:Analgesics, Opioid / Q000008:administration & dosage*; D004992:Ethics, Medical; D003932:Heroin / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008691:Methadone / Q000008:administration & dosage*; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D011364:Professional Practice; D006113:United Kingdom
D000701:Analgesics, Opioid; D003932:Heroin; D008691:Methadone